Literature DB >> 20427658

Genetic variation in FGF20 modulates hippocampal biology.

Herve Lemaitre1, Venkata S Mattay, Fabio Sambataro, Beth Verchinski, Richard E Straub, Joseph H Callicott, Raja Kittappa, Thomas M Hyde, Barbara K Lipska, Joel E Kleinman, Ronald McKay, Daniel R Weinberger.   

Abstract

We explored the effect of single-nucleotide polymorphisms (SNPs) in the fibroblast growth factor 20 gene (FGF20) associated with risk for Parkinson's disease on brain structure and function in a large sample of healthy young-adult human subjects and also in elderly subjects to look at the interaction between genetic variations and age (N = 237; 116 men; 18-87 years). We analyzed high-resolution anatomical magnetic resonance images using voxel-based morphometry, a quantitative neuroanatomical technique. We also measured FGF20 mRNA expression in postmortem human brain tissue to determine the molecular correlates of these SNPs (N = 108; 72 men; 18-74 years). We found that the T allele carriers of rs12720208 in the 3'-untranslated region had relatively larger hippocampal volume (p = 0.0059) and diminished verbal episodic memory (p = 0.048) and showed steeper decreases of hippocampal volume with normal aging (p = 0.026). In postmortem brain, T allele carriers had greater expression of hippocampal FGF20 mRNA (p = 0.037), consistent with a previously characterized microRNA mechanism. The C allele matches a predicted miR-433 microRNA binding domain, whereas the T allele disrupts it, resulting in higher FGF20 protein translation. The strong FGF20 genetic effects in hippocampus are presumably mediated by activation of the FGFR1 (FGF receptor 1), which is expressed in mammalian brain most abundantly in the hippocampus. These associations, from mRNA expression to brain morphology to cognition and an interaction with aging, confirm a role of FGF20 in human brain structure and function during development and aging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427658      PMCID: PMC2909689          DOI: 10.1523/JNEUROSCI.5773-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  29 in total

1.  Intermediate or brainless phenotypes for psychiatric research?

Authors:  A Meyer-Lindenberg
Journal:  Psychol Med       Date:  2010-07       Impact factor: 7.723

2.  Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia.

Authors:  Barbara K Lipska; Amy Deep-Soboslay; Cynthia Shannon Weickert; Thomas M Hyde; Catherine E Martin; Mary M Herman; Joel E Kleinman
Journal:  Biol Psychiatry       Date:  2006-09-15       Impact factor: 13.382

3.  FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain.

Authors:  S Ohmachi; Y Watanabe; T Mikami; N Kusu; T Ibi; A Akaike; N Itoh
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

4.  Fibroblast growth factor receptor-1 is required for long-term potentiation, memory consolidation, and neurogenesis.

Authors:  Mingrui Zhao; Dan Li; Kazuhiro Shimazu; Yong-Xing Zhou; Bai Lu; Chu-Xia Deng
Journal:  Biol Psychiatry       Date:  2007-01-18       Impact factor: 13.382

5.  Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression.

Authors:  R E Straub; B K Lipska; M F Egan; T E Goldberg; J H Callicott; M B Mayhew; R K Vakkalanka; B S Kolachana; J E Kleinman; D R Weinberger
Journal:  Mol Psychiatry       Date:  2007-05-01       Impact factor: 15.992

6.  Factor analysis of neurocognitive tests in a large sample of schizophrenic probands, their siblings, and healthy controls.

Authors:  Margo R Genderson; Dwight Dickinson; Catherine M Diaz-Asper; Michael F Egan; Daniel R Weinberger; Terry E Goldberg
Journal:  Schizophr Res       Date:  2007-06-13       Impact factor: 4.939

7.  FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.

Authors:  Christian Wider; Justus C Dachsel; Alexandra I Soto; Michael G Heckman; Nancy N Diehl; Mei Yue; Sarah Lincoln; Jan O Aasly; Kristoffer Haugarvoll; John Q Trojanowski; Spiridon Papapetropoulos; Deborah Mash; Alex Rajput; Ali H Rajput; J Mark Gibson; Timothy Lynch; Dennis W Dickson; Ryan J Uitti; Zbigniew K Wszolek; Matthew J Farrer; Owen A Ross
Journal:  Mov Disord       Date:  2009-02-15       Impact factor: 10.338

8.  Characterizing the mesencephalon using susceptibility-weighted imaging.

Authors:  E S Manova; C A Habib; A S Boikov; M Ayaz; A Khan; W M Kirsch; D K Kido; E M Haacke
Journal:  AJNR Am J Neuroradiol       Date:  2008-12-26       Impact factor: 3.825

9.  Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein.

Authors:  Gaofeng Wang; Joelle M van der Walt; Gregory Mayhew; Yi-Ju Li; Stephan Züchner; William K Scott; Eden R Martin; Jeffery M Vance
Journal:  Am J Hum Genet       Date:  2008-01-31       Impact factor: 11.025

10.  Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data.

Authors:  Hon-Chung Fung; Sonja Scholz; Mar Matarin; Javier Simón-Sánchez; Dena Hernandez; Angela Britton; J Raphael Gibbs; Carl Langefeld; Matt L Stiegert; Jennifer Schymick; Michael S Okun; Ronald J Mandel; Hubert H Fernandez; Kelly D Foote; Ramón L Rodríguez; Elizabeth Peckham; Fabienne Wavrant De Vrieze; Katrina Gwinn-Hardy; John A Hardy; Andrew Singleton
Journal:  Lancet Neurol       Date:  2006-11       Impact factor: 44.182

View more
  6 in total

Review 1.  MicroRNAs in Parkinson's disease.

Authors:  Maged M Harraz; Ted M Dawson; Valina L Dawson
Journal:  J Chem Neuroanat       Date:  2011-02-02       Impact factor: 3.052

2.  Quantitative assessment of the effect of FGF20 rs1721100 and rs12720208 variant on the risk of sporadic Parkinson's disease: a meta-analysis.

Authors:  Wei Quan; Jia Li; Li Liu; Qinghui Zhang; Yidan Qin; Xiaochen Pei; Jiajun Chen
Journal:  Neurol Sci       Date:  2021-11-29       Impact factor: 3.830

Review 3.  MicroRNAs in Experimental Models of Movement Disorders.

Authors:  Soon-Tae Lee; Manho Kim
Journal:  J Mov Disord       Date:  2011-10-30

Review 4.  The Fibroblast Growth Factor signaling pathway.

Authors:  David M Ornitz; Nobuyuki Itoh
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-03-13       Impact factor: 5.814

5.  Genome-wide SNP scan of pooled DNA reveals nonsense mutation in FGF20 in the scaleless line of featherless chickens.

Authors:  Kirsty L Wells; Yair Hadad; Danny Ben-Avraham; Jossi Hillel; Avigdor Cahaner; Denis J Headon
Journal:  BMC Genomics       Date:  2012-06-19       Impact factor: 3.969

6.  Depressive symptoms are associated with a functional polymorphism in a miR-433 binding site in the FGF20 gene.

Authors:  Karen M Jiménez; Angela J Pereira-Morales; Ana Adan; Sandra Lopez-Leon; Diego A Forero
Journal:  Mol Brain       Date:  2018-09-21       Impact factor: 4.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.